오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - melphalan hydrochloride, quantity: 55.97 mg (equivalent: melphalan, qty 50 mg) - injection, diluent for - excipient ingredients: sodium citrate dihydrate; ethanol; water for injections; propylene glycol - for?the?treatment?of?patients?with?multiple?myeloma?for?whom?oral therapy?is?not?appropriate

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tillomed pharma gmbh - melperone hydrochloride 55,973 mg - eq. melphalan 50 mg - powder and solvent for solution for injection/infusion - 50 mg - melperone hydrochloride 55.973 mg - melphalan

미국 - 영어 - NLM (National Library of Medicine)

oncopeptides, ab - melphalan flufenamide hydrochloride (unii: 3412470a0v) (melphalan flufenamide - unii:f70c5k4786) - pepaxto is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one cd38-directed monoclonal antibody. this indication is approved under accelerated approval based on response rate. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) [see clinical studies (14)] . limitations of use pepaxto is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials [see warnings and precautions (5.5)]. pepaxto is contraindicated in patients with a history of serious hypersensitivity reaction to melphalan flufenamide or melphalan [see adverse reactions (6.1)] . risk summary based on its mechanism of action [see clinical pharmacology (12.1)] , pepaxto ca

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate